Please cite this article as: M. Steiner, V. Brache, D. Taylor, et al., Randomized trial to evaluate contraceptive efficacy, safety and acceptability of a two rod contraceptive implant over four years in the Dominican Republic, Contraception: X, https://doi.org/10. 1016/ j.conx.2019.100006 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 
INTRODUCTION
Sino-implant (II) is a subdermal contraceptive implant system manufactured in China and marketed globally as Levoplant TM . To make Sino-implant (II) more broadly available to women in developing countries, the Bill & Melinda Gates Foundation funded a global initiative coordinated by FHI 360. A key objective of the initiative was to obtain WHO pre-qualification which is necessary for global procurement agencies (e.g., UNFPA and USAID) to distribute the product.
The initial Sino-implant (II) dossier was submitted to the WHO Prequalification Team:
medicines (PQTm) in 2010 with data collected in China in the early 1990s and reviewed by
Steiner et al. [1] WHO PQTm concluded available data were insufficient to warrant prequalification, as the trials did not meet Good Clinical Practice (GCP) guidelines. FHI 360 subsequently undertook a GCP-compliant trial in the Dominican Republic (DR), with the main objective to evaluate the contraceptive efficacy of Sino-implant (II) during four years of use.
Secondary objectives included comparing Sino-implant (II) safety, efficacy, acceptability and PK to Jadelle® during up to 5 years of use.
METHODS
We conducted this Phase III, randomized, active-control, parallel group clinical trial at the PROFAMILIA clinic in Santo Domingo, the DR. The ethical review board at FHI 360 and two review boards in the DR (PROFAMILIA and CONABIOS) approved the protocol. We registered the trial on ClinicalTrials.gov and adhered to the CONSORT guidelines in our reporting of results. [2] A C C E P T E D M A N U S C R I P T
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The study had two treatment groups: Sino-implant (II) (Shanghai Dahua Pharmaceutical Co., Ltd (Dahua)), and an active control, Jadelle® (Bayer Healthcare, Berlin, Germany). Each device consists of two flexible silicone rods loaded with 75mg of levonorgestrel (LNG) -150mg LNG per set. We randomized participants using sequentially numbered, sealed opaque envelopes. We instructed the clinicians to insert (and remove) the assigned contraceptive implant following instructions adapted from Jadelle®'s instructions. [3] To be eligible for the study, women had to be aged 18 to 44 years, not pregnant or lactating and not wishing to become pregnant in the next five years (see Supplement for all inclusion/exclusion criteria). We enrolled eligible participants during the first seven days of their menstrual cycle and confirmed negative pregnancy status per urine pregnancy test (Accu-Tell Rapid Diagnostic, HCG Urine / Serum Cassette, AccuBioTech Co., Ltd, Beijing, China -catalog no. ABT-FT-B2.). The Accu-Tell Rapid Diagnostic test detects hCG concentration of 25 mIU/ml and greater (sensitivity and specificity >99.9%). The urine pregnancy test was repeated at the final visit, and at any other visit where there were signs of pregnancy. A positive urine test was confirmed by ultrasound and/or serum quantitative hCG measurement.
We scheduled follow-up visits at 1, 6, 12, 18, 24, 30, 36, 42, 48, 51, 54, 57 and 60 months postinsertion. We asked a subgroup of 50 participants to attend additional visits 6, 24, 48 and 72 hours, and 7 and 90 days, post-insertion for LNG sampling to compare the initial pharmacokinetic (PK) profiles of the two products. At all regular visits we measured blood pressure and weight; drew blood for determination of total LNG and sex hormone binding included an active control to allow for a direct comparison of total LNG concentrations, safety, and acceptability; the 4:1 allocation ratio was intended to provide sufficient precision for making such comparisons.
The primary efficacy measure was the pregnancy Pearl Index (number of pregnancies per 100
women-years of follow-up) in the Sino-implant (II) group during up to four years of implant use.
Although our initial plans were to follow participants for up to 5 years as a secondary outcome (labelled duration of use of Jadelle®), on February 1, 2016, the independent data and safety monitoring board (DSMB) recommended participant follow-up be truncated at month 48 due to a higher than expected pregnancy rate among the women who had already provided data in the 4 th and 5 th years of Sino-implant (II) use. To assure that we detected any possible early pregnancies present at the 48 -month visit, we decided to simultaneously test both urine and serum samples with the Accu -Tell Rapid Diagnostic test at this exit visit.
Secondary efficacy measures included cumulative probabilities of pregnancy and pregnancy rates at yearly intervals. We reported the pregnancy Pearl Index and pregnancy rates at yearly intervals with 95% confidence intervals (CI) based on a Poisson assumption for mean time to event. We used Kaplan-Meier methods to estimate cumulative probabilities of pregnancy, with 95% CIs derived using the complementary log-log transformation. Although the study is not powered to detect differences in pregnancy risk between the two implants types, we compared the proportions of participants becoming pregnant based on an exact two-sided test.
PPD bio-analytical labs measured total plasma LNG concentrations using a validated highperformance liquid chromatography tandem mass spectrometry (HPLC/MS/MS) assay (interand intra-assay precision, expressed as the coefficient of variation times 100, ranged from 2.72 to 6.04% and from 1.60 to 9.00%, respectively) and serum SHBG using an ADVIA Centaur solid phase two-site chemiluminescent immunoassay.
We reported Cmax and Tmax for each participant undergoing intensive PK sampling, excluding women with detectable LNG at baseline. We estimated corresponding AUC values using the linear-log trapezoidal method and summarized results by implant type using means, standard deviations (SD), 95% CIs, and other descriptive statistics. We compared groups using p-values for tests of no difference and 90% CIs for geometric mean ratios (GMR) of PK parameters.
Although this was not a bioequivalence trial, for descriptive purposes we considered the implant types equivalent with respect to a given PK parameter if the corresponding 90% CI fell in the interval [0.8-1.25] per standard guidance. [5] We summarized total LNG concentration among all
enrolled, and SHBG and the free LNG index (LFI), defined as the ratio of total LNG (nmol/L) to SHBG (nmol/L) concentrations (times 100), in the final 150 enrolled participants, by study visit using descriptive statistics, with no adjustment for multiple comparisons.
For safety outcomes, we compared the percentage of women experiencing AEs within system organ class, the percentage experiencing complications during insertion or removal, and the percentage of implants that broke during removal between groups using Fisher's exact tests.
For acceptability outcomes, we computed cumulative probabilities of early implant removal using Kaplan-Meier methods, with differences in rates assessed using a log-rank test. We compared categorical responses to acceptability questions between treatment groups using Fisher's exact tests. Unless otherwise noted, we conducted all tests at the two-sided α=0.05 significance level, based on allocated treatment group.
RESULTS

Study Subjects
We screened 749 women between October 2011 and July 2013 to randomize 650 participants into the trial that completed follow-up July 2017 (Figure 1 ). Among the 650 enrolled participants, 514 received Sino-implant (II) and 136 received Jadelle® (including 3 random allocation errors discovered during the closeout monitoring visit). Only 10 participants were lost to follow-up and the visit completion rate was greater than 95%. Baseline characteristics were well balanced across groups and are presented in Table 1 .
Of the fifty participants recruited into the PK Population for more intensive assessment of total LNG concentrations (Figure 1 ), we excluded nine (18%) due to detectable LNG at baseline (range: 113-1860 pg/m) leaving 41 participants (22 and 19 in the Sino-implant (II) and Jadelle® groups, respectively) contributing to the estimation of PK parameters. Baseline characteristic for this subgroup were well balanced and similar to the whole group with the exception that women with BMI≥30 kg/m 2 were excluded from the PK Population (data not shown).
Efficacy
In the primary efficacy analysis, the 514 women assigned Sino-implant (II) contributed 1343.9 WY of implant use during up to four years of treatment, resulting in a four-year Pearl Index of 0.74 (95% CI: 0.36-1.37) ( Table 3) . We recorded 11 pregnancies in the study, all among the 514 women assigned to Sino-implant (II): 1, 1, 8, and 1 in years two, three, four, and five of implant use, respectively. Of these 11 pregnancies, we recorded two ectopic pregnancies, four spontaneous and one induced abortion, and four live births including one set of twins without fetal or neonatal abnormalities ( Table 2 ).
The three-year Pearl Index based on 1117. 
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The 136 participants assigned to Jadelle® contributed 353.2 WY of follow-up in the first four years of implant use. We recorded no pregnancies resulting in a Pearl Index of 0.00 (95% CI:
0.00-1.04) ( Table 3 ). The trial was not designed or sufficiently powered to compare the Pearl Indices between the two implant groups.
Sino-implant (II) users who became pregnant had a non-significantly higher mean body weight than the remaining users (73.1 kg versus 66.0 kg: p=0.09). In nine of the eleven women who became pregnant (81.8%), the measured total LNG concentration at the last visit before EDF was below 200 pg/mL and was also below the average LNG concentration among all Sino-implant (II) users at the corresponding sampling visits (Table 2 and Figure 2 ).
Pharmacokinetics -Total LNG Concentrations
Total plasma LNG concentrations in the PK population uniformly exceeded 200 pg/mL within 24 hours of implant insertion in both groups. The mean C max in the Sino-implant (II) and Jadelle® group, respectively, was 833 and 962 pg/mL; mean T max was 5.4 and 4.3 days; and mean AUC 0-6m was 2489 and 2862 pg•months/mL.
In the Sino-implant (II) group, mean concentrations decreased from 428 pg/mL one month after insertion to 310, 252, 220, and 205 pg/mL at months 12, 24, 36, and 48, respectively ( Figure 2 ).
In the Jadelle® group, mean concentrations generally decreased from 453 pg/mL at month one to 314, 310, 276, and 299 pg/mL at months 12, 24, 36, and 48, respectively. The observed trend in
decreasing geometric mean ratios (GMRs) over time was significant (p<0.001) in an exploratory test of no difference in log-linear slopes (see detailed discussion of LNG levels, related SHBG levels and the free LNG Index (FLI) in Supplement).
Safety
Except for menstrual irregularities (experienced by 48.4% and 58.8% of Sino-implant (II) and Jadelle® users, respectively; p=0.03), there were no significant differences in the proportions of women experiencing common AEs.
Twenty-eight participants (5.4%) in the Sino-implant (II) group reported a total of 32 SAEs, including seven that were considered at least possibly related to implant use: two ectopic pregnancies, two ovarian cysts, one episode of cholecystitis, one episode of cholelithiasis, and one case of biliary colic. Five participants (3.7%) in the Jadelle® group reported a total of six SAEs, none of which were considered related to implant use.
Implant Insertion and Removal
Implant insertion took an average of 32.7 (SD: 9.7) and 29.2 (SD: 8.8) seconds in the Sinoimplant (II) and Jadelle® groups, respectively, and the insertion procedure was uniformly considered easy (100%) for both implant types by experienced clinicians. Most participants reported no pain during the insertion procedure (92.4% for Sino-implant (II) and 94.9% for Jadelle®; p=0.35).
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The implant removal took less than 5 minutes for 92.0% and 95.5% of Sino-implant (II) and Jadelle® procedures, respectively, although providers were less likely to report that Sino-implant (II) was easy to remove (82.4% and 93.2%; p<0.01). Most participants reported no pain during the removal procedure (83.6% for Sino-implant (II) and 88.9% for Jadelle®; p=0.14).
The total breakage rate during removal was significantly greater for Sino-implant (II) than for Jadelle® (16.3% versus 3.1%; p<0.001), and a second clinic visit was required to ensure that the Sino-implant (II) was completely removed in 13 (2.7%) instances. One of the identified explanations for the high breakage rate was that the site was not following the removal instructions and were applying twisting/torque motion instead of pulling when withdrawing the rods. Additional training of site clinicians re-emphasized the instructions with respect to minimizing the use of twisting/torque when withdrawing the rods. Still later, the clinic began using less sharp and slightly larger Crile forceps instead of mosquito clamps for withdrawing the rods. The breakage rate in the Sino-implant (II) group generally decreased with each intervention: 33.3% prior to re-training; 17.6% after training to minimize twisting/torque; and 8.3% after the site began using Crile forceps. However, the Sino-implant (II) breakage rate increased to 24.8% in the three-month period following the decision to truncate follow-up (when the number of removals was greatest) and remained somewhat elevated thereafter (14.1%).
Acceptability
Year-four continuation rates were similar for Sino-implant (II) and Jadelle® (41% vs. 38%; What might explain these somewhat different results across studies? The trial in the DR was the more rigorous study from a design and implementation perspective (e.g., randomized; low lossto-follow-up; site inspection per WHO GCP). How much of the difference in efficacy between studies in China and the DR is due to: 1) differences in sexual behavior and other covariates related to the underlying risk of pregnancy (e.g. age); 2) ethnic/genetic differences in
pharmacokinetics and pharmacodynamics of LNG; 3) random variability and inherent challenges of measuring pregnancy outcomes or 4) data quality (e.g., possibility of participants accessing abortions without site staff knowledge) is not known.
Sexual behavior is notoriously difficult to measure [7] and most modern contraceptive efficacy trials [8] [9] [10] make no attempts to control for this covariate because doing so might introduce additional confounding. Participants in the DR trial were on average younger than in the China study at enrollment (23.6 vs 33.9 years old, respectively) which is perhaps associated with increased sexual frequency and somewhat higher fecundity. [11] Moreover, participants in the DR trial had somewhat higher BMI than participants in the China study (24.6 vs, 23.7, respectively) which also has been shown to increase the risk of pregnancy in some, but not all, contraceptive implant trials. [12] Thus, it is possible that participants in the DR trial were exposed to higher underlying risk of pregnancy than women included in the most recent China study.
Differences in metabolism of hormones like LNG and MPA between Asian and non-Asian females as well as males is well documented. [13] [14] [15] LNG levels were generally higher in the China study than in the DR trial and did not show the same downward trend after Year 3.
However, the PK outcome related to the free drug concentration (FLI), presumed to be more highly correlated with pregnancy prevention than total LNG [16] [17] [18] was stable after Year 3 in the DR (see PK Supplement) but declined in China. We must be careful not to overinterpret PK differences and temporal trends because these are non-randomized comparisons.
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Given the expected rarity of pregnancy in implant trials, the study was not powered to detect, nor did it identify, significant differences in pregnancy rates between implant types. However, we did observe a significantly higher pregnancy rate in the 4 th year of Sino-implant (II) use than in the first three years combined. Of the 8 pregnancies in the 4 th year, one chemical pregnancy was only detected because of the deviation from the pregnancy testing algorithm specified in the protocol and a second pregnancy was included in the analysis because we could not determine with certainty that the EDF was outside the follow-up period. This illustrates the challenge of conducting contraceptive trials with the inherent difficulty of dating conception as well as the fact that 30-50% of pregnancies are not viable and end spontaneously in early pregnancy loss.
[19] The latter can lead to substantially different efficacy outcomes depending on the frequency of pregnancy testing and the sensitivity of tests used. Finally, differences in data quality can never be ruled out for potentially explaining differences in efficacy.
We observed a higher than expected breakage rate for Sino-implant (II) at the time of removal. for their work to ready the analysis data set. We thank Kirsten Vogelsong and Mark Milad for the review and comments on the draft manuscript. The authors do not declare any conflict of interest. 2 Ambiguous urine test result, but serum hCG results were elevated and consistent with pregnancy. Repeated ultrasounds showed no evidence of pregnancy, and she reported spontaneous menses 16 days after study exit. 3 Negative urine test, but a parallel qualitative hCG test was weakly positive and a quantitative hCG test was elevated (10.7 mIU/mL). She was positive by urine test 6 days later, but repeated ultrasounds showed no evidence of pregnancy and she reported spontaneous menses 12 days after study exit.
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Page | 23 Complete Inclusion/Exclusion Criteria To be eligible for the study, women had to be: in good general health; aged 18 to 44 years; not pregnant or lactating; not wishing to become pregnant in the next five years; requesting longacting reversible contraception; > 9 months after last injection of Depo Provera, > 3 months after last injection of combined injectable contraceptive, > than 1 week after last intake of LNGcontaining pill or implant removal; able to understand information about study participation; willing to sign consent form; and able to return for follow-up visits over five years. Exclusion interfere with adherence to study requirements or complicate data interpretation; and BMI > 30kg/m 2 (excluded only from the pharmacokinetic (PK) subgroup).
Pharmacokinetics
A C C E P T E D M A N U S C R I P T detected in the specimen. and nine (0.2%) gross outliers (≥3000 pg/mL on or after month one).
Total plasma LNG concentrations in the PK population uniformly exceeded 200 pg/mL within 24 hours of implant insertion in both groups. The mean C max in the Sino-implant (II) and Jadelle® group, respectively, was 833 and 962 pg/mL; mean T max was 5.4 and 4.3 days; and mean AUC 0-6m was 2489 and 2862 pg•months/mL. Given this was not a traditional bioavailability trial and had less frequent sampling, the C max and T max may be somewhat imprecise estimates.
In the Sino-implant (II) group, mean concentrations decreased from 428 pg/mL one month after insertion to 310, 252, 220, and 205 pg/mL at months 12, 24, 36, and 48, respectively (Figure 2 ).
In the Jadelle® group, mean concentrations generally decreased from 453 pg/mL at month one to 314, 310, 276, and 299 pg/mL at months 12, 24, 36, and 48, respectively. The observed trend in decreasing geometric mean ratios (GMRs) over time was significant (p<0.001) in an exploratory test of no difference in log-linear slopes A significantly higher percentage of Sino-implant (II) participants had total LNG concentrations below 200 pg/mL at one or more time points during ACCEPTED MANUSCRIPT
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Page | 28 the first 4 years of follow-up (288 (56.0%) Sino-implant (II) versus 47 (34.6% of Jadelle usersp<0.01). Likewise, forty-three (8.4%) Sino-implant (II) users had total LNG concentrations below 100 pg/mL at one or more time points during follow-up (none before month 18), compared to one (0.7%) Jadelle® user (p<0.001).
SHBG and Free LNG Index (FLI) During up to Forty-Eight Months of Use
There was a rapid reduction in SHBG levels immediately following insertion of either implant type in the PK population: from a mean of 91.5 nmol/L at baseline to a minimum of 33.9 nmol/L at month 1 for Sino-implant (II), and from 86.7 to 32.1 nmol/L at month 3 for Jadelle®.
Combined with rising total LNG concentrations, there was a corresponding rapid increase in the FLI, which achieved a maximum mean of 5.2 at day 7 for Sino-implant (II) and 5.1 at month 1 for Jadelle®. 
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